Nascent Biotech (NBIO) 10-K 1 Jul 24 2024 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Mar. 31, 2024	Jun. 28, 2024	Sep. 30, 2023
Cover [Abstract]
Entity Registrant Name	NASCENT BIOTECH INC.
Entity Central Index Key	0001622057
Document Type	10-K
Amendment Flag	false
Entity Voluntary Filers	No
Current Fiscal Year End Date	--03-31
Entity Well Known Seasoned Issuer	No
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Mar. 31, 2024
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Entity Common Stock Shares Outstanding		172,202,165
Entity Public Float			$ 19,168,087
Document Annual Report	true
Document Transition Report	false
Document Fin Stmt Error Correction Flag	false
Entity File Number	000-55299
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	46-5001940
Entity Address Address Line 1	631 US Hwy 1 Suite 407
Entity Address Address Line 2	Suite 407
Entity Address City Or Town	N Palm Beach
Entity Address State Or Province	FL
Entity Address Postal Zip Code	33408
City Area Code	612
Local Phone Number	961-5656
Entity Interactive Data Current	Yes
Auditor Name	Fruci & Associates II, PLLC
Auditor Firm Id	5525
Auditor Location	Spokane, Washington

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Current assets:
Cash	$ 372,120	$ 172,186
Prepaid	180,000	82,816
Total current assets	552,120	255,002
Total assets	552,120	255,002
Current liabilities:
Accounts payable and accrued liabilities	686,294	498,122
Convertible note- net of discount	122,500	389,591
Derivative liability	0	663,426
Total current liabilities	808,794	1,551,139
Total liabilities	808,794	1,551,139
Commitments and contingencies	0	0
Stockholders' equity:
Preferred stock, $0.001 par value,50,000,000 authorized, zero Series A issued and outstanding, respectively	0	0
Common stock, $0.001 par value, 500,000,000 authorized, 170,594,165 and 131,764,348 issued and outstanding, respectively	170,594	131,764
Additional paid-in capital	23,833,189	20,194,874
Accumulated deficit	(24,260,457)	(21,622,775)
Total stockholders' equity (deficit)	(256,674)	(1,296,137)
Total liabilities and stockholders' equity (deficit)	$ 552,120	$ 255,002

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2024	Mar. 31, 2023
Stockholders deficit
Preferred stock shares par value	$ 0.001	$ 0.001
Preferred stock shares authorized	50,000,000	50,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock shares par value	$ 0.001	$ 0.001
Common stock shares authorized	500,000,000	500,000,000
Common stock shares issued	170,594,165	131,764,348
Common stock shares outstanding	170,594,165	131,764,348

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Consulting expense	$ 1,303,342	$ 1,096,245
General and administrative expense	403,589	405,295
Clinical trials	92,466	383,688
Product manufacturing and vial filling	319,507	0
Research and development	110,975	270,529
Total operating expense	2,229,879	2,155,757
Income (loss) from operations	(2,229,879)	(2,155,757)
Other income (expense):
Interest income	5,265	274
Interest expense	(385,236)	(1,566,919)
Financing costs	0	(5,124)
Gain on debt forgiveness	50,000	28,000
Original interest debt discount	0	(156,229)
Gain on change in fair value of derivative liabilities	472,168	1,054,786
Total other income (expense)	142,197	(645,212)
Net income (loss) before income tax	(2,087,682)	(2,800,969)
Income tax	0	0
Net income (loss)	$ (2,087,682)	$ (2,800,969)
Net income (loss) per share, basic and diluted	$ (0.01)	$ (0.02)
Weighted average number of shares outstanding, basic and diluted	155,744,233	118,569,028

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT - USD ($)	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balance, shares at Mar. 31, 2022		111,313,175
Balance, amount at Mar. 31, 2022	$ (671,476)	$ 111,313	$ 18,039,017	$ (18,821,806)
Common stock issued for service, shares		1,000,000
Common stock issued for service, amount	60,000	$ 1,000	59,000	0
Common stock issued for conversion of payables, shares		37,700
Common stock issued for conversion of payables, amount	9,275	$ 38	9,237	0
Common stock issued to related parties for service, shares		3,815,414
Common stock issued to related parties for service, amount	624,320	$ 3,815	620,505	0
Common stock issued for the conversion of debt, shares		11,398,059
Common stock issued for the conversion of debt, amount	1,023,974	$ 11,398	1,012,576	0
Common stock issued for the conversion of warrants, shares		4,200,000
Common stock issued for the conversion of warrants, amount	208,000	$ 4,200	203,800
Warrants issued with convertible notes	178,739	0	178,739	0
Stock option expense	72,000	0	72,000	0
Net loss	(2,800,969)	$ 0	0	(2,800,969)
Balance, shares at Mar. 31, 2023		131,764,348
Balance, amount at Mar. 31, 2023	(1,296,137)	$ 131,764	20,194,874	(21,622,775)
Common stock issued for service, shares		386,250
Common stock issued for service, amount	35,850	$ 386	35,464	0
Common stock issued to related parties for service, shares		7,186,387
Common stock issued to related parties for service, amount	773,241	$ 7,187	766,054	0
Stock option expense	48,000	0	48,000	0
Net loss	(2,087,682)	$ 0	0	(2,087,682)
Common stock issued for cash, shares		19,970,000
Common stock issued for cash, amount	1,561,000	$ 19,970	1,541,030	0
Common stock issued for the conversion of stock option, shares		500,000
Common stock issued for the conversion of stock option, amount	25,000	$ 50,000	24,500	0
Common stock issued for conversion of debt, shares		10,787,180
Common stock issued for conversion of debt, amount	492,796	$ 10,787	482,009	0
Change in derivative at conversion	191,258	0	191,258	0
Down round of warrants	0	$ 0	550,000	(550,000)
Balance, shares at Mar. 31, 2024		170,594,165
Balance, amount at Mar. 31, 2024	$ (256,674)	$ 170,594	$ 23,833,189	$ (24,260,457)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (2,087,682)	$ (2,800,969)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	60,850	60,000
Stock based compensation - related parties	773,241	624,320
(Gain) loss in fair value of derivative liability	(472,168)	(1,054,786)
Debt discount amortization	377,909	1,343,277
Loss on notes	(50,000)	286,265
Stock Option expense	48,000	72,000
Changes in operating assets and liabilities:
Accounts receivable	0	0
Prepaid	(97,184)	(71,816)
Accounts payable and accrued expenses	260,968	(245,519)
Net cash provided by (used in) operating activities	(1,186,066)	(1,787,228)
Cash flows from financing activities:
Common stock issued for cash	1,561,000	0
Proceeds from convertible note	225,000	1,932,000
Common stock issued for the exercise of warrants	0	208,000
Repayments of convertible notes	(400,000)	(275,000)
Net cash provided (used) by financing activities	1,386,000	1,865,000
Net increase (decrease) in cash	199,934	77,772
Cash -beginning of year	172,186	94,414
Cash -end of period	372,120	172,186
SUPPLEMENT DISCLOSURES:
Interest paid	0	11,135
Income taxes paid	0	0
NON MONETARY TRANSACTIONS
Common stock issued for convertible debt	673,267	23,974
Common stock issued for accounts payable	0	9,275
Initial discount from derivatives	$ 0	$ 178,739

ORGANIZATION AND NATURE OF OPER

ORGANIZATION AND NATURE OF OPERATIONS	12 Months Ended
	Mar. 31, 2024
ORGANIZATION AND NATURE OF OPERATIONS
ORGANIZATION AND NATURE OF OPERATIONS	NOTE 1 – ORGANIZATION AND NATURE OF OPERATIONS Nascent Biotech, Inc (“Nascent “the Company”) was incorporated on March 3, 2014 under the laws of the State of Nevada. On July 15, 2014 Biotech entered into a reverse merger with Jin-En Group International Holding Company (Jin-En). Jin-En issued 7,500,200 shares of its common stock for all the outstanding shares of Nascent Biotech, Inc. In addition, Jin-En cancelled 15,000,000 shares of its common stock. Prior to the merger Jin-En had 22,829,400 shares outstanding. Jin-En changed its name to Nascent Biotech, Inc. Jin-En had $19,000 of net liabilities at the date of the merger. The Company is actively developing its primary asset Pritumumab for the treatment of brain cancer and pancreatic cancer. Nascent is also actively researching other cancers that have a high probability of benefiting from the therapeutic effects of Pritumumab because they share a common target. Nascent is a clinical stage biopharmaceutical company that focuses on biologic drug candidates that are preparing for initial clinical testing for the treatment of brain and pancreatic cancer. The Company has completed its phase one clinical trials and clearance was received from the FDA for the Company to commence its phase 2 clinical trials.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Mar. 31, 2024
SIGNIFICANT ACCOUNTING POLICIES
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles. The Company has elected a fiscal year ending on March 31. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Nascent Biotech, Inc. and its wholly-owned subsidiary Nascent Biologics, Inc, which has been inactive since March 2015. All intercompany accounts and transactions have been eliminated. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company as of March 31, 2024 did not have any cash equivalents. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the periods. The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition, and results of operations is highly uncertain and subject to change. We considered the potential impact of the COVID-19 pandemic on our estimates and assumptions and there was not a material impact to our consolidated financial statements as of and for the year ended March 31, 2024. Actual results could differ from estimates making it reasonably possible that a change in the estimates could occur in the near term. Revenue recognition In April 2016, the FASB issued ASU 2016–10 Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. The amendments in this Update do not change the core principle of the guidance in Topic 606. Rather, the amendments in this Update clarify the following two aspects of Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. Topic 606 includes implementation guidance on (a) contracts with customers to transfer goods and services in exchange for consideration and (b) determining whether an entity’s promise to grant a license provides a customer with either a right to use the entity’s intellectual property (which is satisfied at a point in time) or a right to access the entity’s intellectual property (which is satisfied over time). The amendments are intended to render more detailed implementation guidance with the expectation to reduce the degree of judgement necessary to comply with Topic 606. ASC Topic 606 prescribes a new five-step model entities should follow in order to recognize revenue in accordance with the core principle. These five steps are: 1. Identify the contract(s) with a customer. 2. Identify the performance obligations in the contract. 3. Determine the transaction price. 4. Allocate the transaction price to the performance obligations in the contract. 5. Recognize revenue when (or as) the entity satisfied the performance obligations. The Company implemented the transition using the modified retrospective method of transition. The funds are not earned on milestones that have not been reached per the contract. Based on the cut off treatment of the recognition of revenue per the milestones specific to the license agreements, the Company has determined that there are no adjustments in the value of the revenue recognized from these contracts. The Company had one revenue stream, which was the milestone payments of the license agreement with BioRay Pharmaceutical which is not earned or billed until the milestone per the agreement is met. The license agreement for this revenue stream was terminated. The Company did not receive any revenue for the year ended March 31, 2024. Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the fair value recognition provision of the Financial Accounting Standards Board(“FASB”) Accounting Standards Codification (“ASC”) No 718. The Company issues restricted stock to employees and consultants for their services. Cost of these transactions are measured at fair value of the equity instrument issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as the expense in the period granted. The Company recognized consulting expense and a corresponding increase to the additional paid in capital related to the stock issued for services. For agreements requiring future services the consulting expense is to be recognized ratably over the requisite service period. Research and Development Expense Research and development costs are expensed in the period they are incurred in accordance with ASC 730, Research and Development unless they meet specific criteria related to technical, market and financial feasibility, as determined by management, including but not limited to the establishment of a clearly defined future alternative use for the product, and the availability of adequate resources to complete the project. If all criteria are met, the costs are deferred and amortized over the expected useful life of the project or expensed as research and development as the material are consumed or written off if a product is abandoned. At March 31, 2024 and 2023, the Company had zero capitalization associated with materials held with a future alternative use. The cost of these materials was expensed as research and development as the materials are consumed or designated for usage. As the Company is preparing to begin clinical studies using a dose escalation method, it is not feasible to determine if the additional product will be needed for the brain cancer studies. Income Taxes Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company accounts for income taxes under the provisions of FASB ASC 740, Accounting for Income Taxes Basic and Diluted Net Income (Loss) per Share Basic net income (loss) per share calculations are calculated on the basis of the weighted average number of common shares outstanding during the year. During the year ended March 31, 2024 the Company had a net loss so the options and warrants outstanding were not part the loss per share calculation as they would be antidilutive. Diluted income (loss) per share calculations includes the dilutive effect of warrants and options on the weighted average of the per share calculation. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, accounts payable and accrued expenses and shareholder loans. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. As defined in (Financial Accounting Standards Board ASC 820), fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilized the market data of similar entities in its industry or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. FASB ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). The three levels of the fair value hierarchy are as follows: Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities, and listed equities. Level 2 - Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or indirectly observable as of the reported date and includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options, and collars. Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value As of March 31, 2024 the Company believes the amounts reported for cash, payables, accrued liabilities and amounts due to related parties approximate their fair values due to the nature or duration of these instruments. The following table represents the change in the fair value of the derivative liabilities during the year ended March 31, 2024: Level 1 Level 2 Level 3 Balance at March 31, 2022 $ - $ - $ - Change in fair value at initial issuance - - 178,739 Change in fair value at conversion (570,099 ) Change in fair value of the derivative - - 1,054,786 Balance at March 31, 2023 $ - $ - $ 663,426 Change in fair value at initial issuance - Change in fair value at conversion (191,258 ) Change in fair value of the derivative (472,168 ) Balance at March 31, 2024 $ - $ - $ -

GOING CONCERN

GOING CONCERN	12 Months Ended
	Mar. 31, 2024
GOING CONCERN
GOING CONCERN	NOTE 3 – GOING CONCERN The Company’s consolidated financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company, as shown in the accompanying consolidated balance sheets, has working capital deficit of $256,674 and an accumulated deficit of $24,260,457 as of March 31, 2024. The Company does not have a source of revenue to cover its operating costs. These factors raise substantial doubt about the company’s ability to continue as a going concern. The Company will engage in research and development activities that must be satisfied in cash secured through outside funding. The Company will offer noncash consideration and seek equity lines as a means of financing its operations. If the Company is unable to obtain revenue producing contracts or financing or if the revenue or financing it does obtain is insufficient to cover any operating losses it may incur, it may substantially curtail or terminate its operations or seek other business opportunities through strategic alliances, acquisitions or other arrangements that may dilute the interests of existing stockholders.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Mar. 31, 2024
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	NOTE 4 – RELATED PARTY TRANSACTIONS On September 1, 2020, the Company entered five-year compensation agreements with two of its officers and an independent director. Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers and directors are entitled to additional future shares so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company. In addition, the officers ae entitled to future bonuses including a signing bonus totaling $170,000 plus additional bonuses based on their performance. Officer and Director Fiscal Year Annualized Compensation Base Being Paid Non-dilutive shares percentage President and CEO (2) $ 252,000 12 % Chief Financial Officer (1) $ 180,000 6 % Director (3) $ 20,000 - Total $ 452,000 18 % For the year ended March 31, 2024: (1) The Chief Financial Officers was paid $180,000 in cash. (2) The President and Chief Executive Officer was paid $252,000 in cash. (3) The director of the Company was paid $20,000 in director fees which was paid in stock. The following table sets forth the shares earned under these contracts from inception through year ended March 31, 2024: 24,000Officer and Director Initial Share Awards Under the Contracts Additional Shares Earned to Maintain Ownership Percentage Total Shares Earned President 1,028,910 14,712,669 15,741,579 Chief Financial Officer 617,346 7,588,673 8,206,019 Total 1,646,256 22,301,342 23,947,598 During the year ended March 31, 2023 the Company issued 3,815,414 shares of common stock with a value of $624,320 to three related parties for service. During the year ended March 31, 2024 the Company issued 7,186,385 shares of common stock with a value of $773,241 to three related parties for service.

LICENSE SETTLEMENT

LICENSE SETTLEMENT	12 Months Ended
	Mar. 31, 2024
LICENSE SETTLEMENT
LICENSE SETTLEMENT	NOTE 5 – LICENSE SETTLEMENT On October 12, 2017, the Company signed a consulting agreement with a former license holder. Under the terms of the agreement the Company, commencing February 1, 2018 will pay the consultant $1,000 per month for 24 months. In addition, the Company paid the consultant an additional $24,000 during the term of the agreement at the Company’s discretion. In return, the consultant forgave all royalty payments plus any past claims to the product per the previous agreement dated September 21, 2015, plus provide consulting services to the Company as directed by the Company. As of September 20, 2022 the consultant was paid in full and released the Company of any claims the former consultant held.

EQUITY

EQUITY	12 Months Ended
	Mar. 31, 2024
EQUITY
EQUITY	NOTE 6 – EQUITY On July 9, 2020, the Company increased its authorized shares to 550,000,000 consisting of 50,000,000 preferred shares and 500,000,000 common shares all at par value $0.001. Preferred Stock On July 10, 2019, the Company filed an amended articles of Incorporation designating 1,500,000 shares of preferred stock as Series A non-voting Convertible preferred shares convertible into common stock at four shares of common for each one share of preferred. As of March 31, 2024 and 2023 there we no outstanding preferred shares. Common Stock During the year ended March 31, 2023 the Company issued 37,700 shares of common stock with a value of $9,275 for accounts payable. During the year ended March 31, 2023, the Company issued 1,000,000 shares of common stock for clinical consulting with a value of $60,000. During the year ended March 31, 2023, the Company 4,200,000 shares of common stock for the conversion of 4,200,000 warrants with a value of $208,000 received in cash. During the year ended March 31, 2023 , the Company issued 3,815,414 shares of common stock with a value of $624,320 to three related parties for service. During the year ended March 31, 2023 the Company issued 11,398,059 shares of common stock with a value of $1,023,974 for the conversion of debt and accrued interest. During the year ended March 31, 2024 , the Company issued 7,186,385 shares of common stock with a value of $773,241 to three related parties for service. During the year ended March 31, 2024 the Company issued 10,787,180 shares of common stock with a value of $684,054 for the conversion of debt and accrued interest. During the year ended March 31, 2024 the Company issued 19,970,000 shares of common stock with a value of $1,561,000 for cash. During the year ended March 31, 2024 the Company issued 886,250 shares of common stock with a value of $60,850 of which 386,250 shares with a value of $35,850 were for service and 500,000 shares of the shares as conversion of options paid by the accounts payable of one party of $25,000.

OPTIONS

OPTIONS	12 Months Ended
	Mar. 31, 2024
OPTIONS
OPTIONS	NOTE 7 – OPTIONS The Company under its 2015 option plan issues options to various officers, directors, and consultants. The options vest in equal annual installments over a five year period with the first 20% vested when the options were granted. All of the options are exercisable at a purchase price based on the last trading price of the Company’s common stock on the date of grant and have a term of 10 years. On April 1, 2016, the Company issued 40,000 options to a consultant under the 2015 option program. The options are exercisable into the Company’s common stock at $0.30 per share, have term of 10 years and vest in 5 equal annual installments with the first installment vesting on the date of grant. This award to a nonemployee is revalued at each reporting period until completion of services. On April 1, 2016, the Company entered a consulting agreement under which the consultant was granted 30,000 options. In addition, the consultant received additional option grants of 30,000 options on April 1, 2017 and 40,000 options on April 1, 2018. The options are exercisable into the Company’s common stock at $0.30 per share, have term of 10 years and vest in 5 equal annual installments with the first installment vesting on the date of grant. On July 20, 2016, the Company granted from the 2015 Option Program 300,000 options each to three officers and directors for a total of 900,000 options being granted. The options are exercisable into the Company’s common stock at an exercise price of $0.301 per share and were vested and expensed at the date of issuance. The fair value at date of granted was determined to be $484,205. On April 1, 2018, the Company granted from the 2015 Option Program 40,000 options to one consultant. The options are exercisable into the Company’s common stock at an exercise price of $0.25 per share and were vested and expensed at the date of issuance. The fair value at date of granted was determined to be $9,991. On November 17, 2022 the Company issued 500,000 options to one individual with an exercise price of $0.10 per share. The options have a 5 year life and vested 250,000 options at inception and 25,000 options per month thereafter until fully vested. The options were fair valued using a volatility of 250%, discount rate of 4.35% at $114,531 to be fully amortized over the 5 year period or at the date of conversion, whichever comes first. The options were converted by the option holder with accrued payables of $25,000. During the years ended March 31, 2024 and 2023, the Company expensed $48,000 and $72,000 respectively related to its option awards. The unrecognized future balance to be expensed over the remaining vesting term of the options is zero as of March 31, 2024. The following sets forth the options granted and outstanding during the years ended March 31, 2024 and 2023: Options Weighted Average Exercise Price Weighted Average Remaining Contract Life Number of Options Exercisable Intrinsic Value Outstanding at March 31, 2022 930,000 $ 0.34 3.80 930,000 $ -- Granted 500,000 0.18 4.75 -- -- Exercised -- -- -- -- -- Forfeited -- -- -- -- -- Outstanding at March 31, 2023 1,430,000 $ 0.28 3.81 930,000 $ -- Granted -- -- -- -- -- Exercised (500,000 ) -- -- -- -- Forfeited -- -- -- -- Outstanding at March 31, 2024 930,000 $ 0.34 2.81 930,000 $ --

WARRANTS

WARRANTS	12 Months Ended
	Mar. 31, 2024
WARRANTS
WARRANTS	NOTE 8 – WARRANTS During the year ended March 31, 2021, the Company granted 3,700,000 warrants to four entities as part of the issuance of 740,000 Series A convertible preferred shares. The warrants expire in two years from grant date and are convertible into common stock at $0.15 per share. The warrants contain an anti-dilution clause which become effective if any instrument is issued after the warrant issuance is converted into common stock at a price lower than the warrant conversion price. The Company used the Black Scholes Pricing model to estimate the fair value of the warrants as of grant date, using the following key inputs: market prices of the Company’s common stock at dates of grant between $0.08-0.11 per share, conversion price of $0.15, volatility of 312.5%-314.49% and discount rate of 0.14-0.16%. Based on the fair value of the common stock of $437,000 and value of the warrants of $349,605 the fair value of the warrants was calculated to be 41% of the total value or $303,000. During the year ended March 31, 2021 the valuation resulted in a deemed dividend from the down round calculation of $555,000 with a recalculated conversion price change to $0.04 per share. On April 7, 2022, the Company issued 500,000 warrants as part of a convertible note issued the same date. The Company used the Black Scholes Pricing model to estimate the fair value of the warrants as of grant date using the following key inputs; market prices of the Company’s stock at date of grant of $0.08 per share, conversion price of $0.12 per share, volatility of 132% and discount of 1.78%. The fair value of the warrants were calculated to be $ 26,000 and was used to allocate the proceeds to the two elements based on the relative fair value of the debt instruments without the warrants and of the warrants at the time of issuance. The portion of the proceeds were allocated to the warrants of $21,336 is accounted for as paid in capital. As of March 31, 2023 the 500,000 warrants were converted into 500,000 shares of common stock with a value of $60,000. On August 31, 2022 the Company issued 750,000 warrants as part of a convertible note issued the same date. The Company used the Black Scholes Pricing model to estimate the fair value of the warrants as of grant date using the following key inputs; market prices of the Company’s stock at date of grant of $0.41 per share, conversion price of $0.60 per share, volatility of 137% and discount of 3.50%. The fair value of the warrants were calculated to be $ 188,760 and was used to allocate the proceeds to the two elements based on the relative fair value of the debt instruments without the warrants and of the warrants at the time of issuance. The portion of the proceeds that were allocated to the warrants of $9,902 is accounted for as paid in capital. On September 2, 2022 the Company issued 250,000 warrants as part of a convertible note issued the same date. The Company used the Black Scholes Pricing model to estimate the fair value of the warrants as of grant date using the following key inputs; market prices of the Company’s stock at date of grant of $0.345 per share, conversion price of $0.60 per share, volatility of 137% and discount of 3.47%. The fair value of the warrants were calculated to be $50,273 and was used to allocate the proceeds to the two elements based on the relative fair value of the debt instruments without the warrants and of the warrants at the time of issuance. The portion of the proceeds were allocated to the warrants of $2,484 is accounted for as paid in capital. The 1,000,000 warrants outstanding contain an anti-dilution clause which become effective if any instrument is issued after the warrant issuance is converted into common stock at a price lower than the warrant conversion price. During the year ended March 31, 2024 31, 2023 the valuation resulted in a deemed dividend from the down round calculation of $550,000 with a recalculated conversion price change to $0.05 per share. On January 30, 2024 the Company issued 250,000 warrants as part of purchase, for cash, of 1,000,000 share of common stock. The warrant expires on January 29, 2027. The Company used the Black Scholes Pricing model to estimate the fair value of the warrants as of grant date using the following key inputs; market prices of the Company’s stock at date of grant of $0.11 per share, conversion price of $0.60 per share, volatility of 158% and discount of 5.20%. The fair value of the warrants were calculated to be $18,280. The weighted average remaining life and intrinsic value of the warrants as of March 31, 2024 was. Warrants Weighted Average Exercise Price Weighted Average Remaining Contract Life Intrinsic Value Outstanding at March 31, 2022 3,700,000 $ 0.04 1.35 $ - Granted 1,000,000 0.60 1.75 - Exercised (3,700,000 ) - -- - Expired -- - -- - Outstanding at March 31, 2023 1,000,000 $ 0.60 1.50 $ - Granted 250,000 0.60 2.75 Exercised -- - -- - Expired -- - -- - Outstanding at March 31, 2024 1,250,000 $ 0.16 .95 $ 134,500 As of March 31, 2024 there were 1,250,000 warrants outstanding.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Mar. 31, 2024
INCOME TAXES
INCOME TAXES	NOTE 9 – INCOME TAXES At March 31, 2024 and 2023 the Company had federal net operating loss carry forwards of approximately $14,783,216 and $13,544,358, respectively. Components of net deferred tax assets, including a valuation allowance, are as follows at March 31, 2024 and 2023: March 31, 2024 March 31, 2023 Deferred tax assets: Net operating loss $ 1,238,858 $ 1,757,783 Less: Valuation allowance (1,238,858 ) (1,757,783 ) Net deferred tax assets $ - $ - In assessing the recovery of the deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in the periods in which those temporary differences become deductible. Management considers the scheduled reversals of future deferred tax assets, projected future taxable income, and tax planning strategies in making this assessment. As a result, management determined it was more likely than not the deferred tax assets would not be realized as of March 31, 2024. Based on the corporation tax rates the Company calculated the deferred tax asset for the years ended March 31, 2024 and 2023 at 21%. The Company, due to its losses, has not filed US Corporate tax returns and is subject to examination back to March 31, 2015.

CONVERTIBLE DEBT

CONVERTIBLE DEBT	12 Months Ended
	Mar. 31, 2024
CONVERTIBLE DEBT
CONVERTIBLE DEBT	NOTE 10 – CONVERTIBLE DEBT On August 31, 2022 the Company entered into an agreement with an unrelated third party for convertible debentures totaling $1,500,000. The first $500,000 was paid at closing with the second $500,000 paid on September 20, 2022, upon filing of an S-1 Registration, and the third $500,000 paid on September 27, 2022, upon the S-1 becoming effective. Each debenture matures one year from date of issuance. The interest rate for each debenture is six percent (6%) per annum and the Debenture may be converted at the lesser of $0.30 per share or eighty percent (80%) of the lowest VWAP of the Company’s common stock for ten consecutive trading days immediately prior to the conversion date and carried an original discount of 3% of the debenture face value. The Company also issued a warrant to purchase 750,000 shares of the Company’s common stock for a period of two years, expiring on August 30, 2024, at an exercise price of $0.60 per share. As part of the agreement the Company filed an S-1 registration statement registering the underlying common shares for the debenture conversion and the warrants. The initial derivatives were calculated for each debenture as follows: 1. Debenture 1- risk free interest of 3.50%, volatility of 137% and expected life of 1.00 years 2. Debenture 2- risk free interest of 4.03%, volatility of 140% and expected life of 1.00 years 3. Debenture 3- risk free interest of 3.98%, volatility of 141% and expected life of 1.00 years During the period ended March 31, 2023, the Company issued 9,539,197 shares of common stock with a value of $823,975 for the conversion of $800,000 of convertible note and $23,975 in interest, leaving a balance due of $700,000 of convertible notes plus accrued interest. On June 29, 2023 the Company signed a redemption agreement, amended on August 31, 2023, with the debentures owner pertaining to the outstanding principal balance of $400,000. Under the terms of the agreement the Company paid the debenture owner $50,000 on August 24, 2023. The terms of the agreement requires principal payments of $50,000, which was made before September 30, 2023, $50,000 to be paid on or before October 31, 2023 and the balance of $250,000 on or before December 31, 2023. The debenture owner has agreed not to convert any of the principal or interest to common stock through December 31, 2023 and if the terms of the agreement are met will forgive any interest on the outstanding amounts of the debentures. On October 30, 2023 ,the Company paid $50,000 against the note outstanding per the settlement agreement leaving a balance due on December 31, 2023 of $250,000. On December 15, 2023 the balance of the note of $250,000 was paid in full. On September 2, 2022 the Company entered into an agreement with an unrelated third party for convertible debentures totaling $500,000. The first $250,000 was paid at closing with the second $250,000 to be paid upon the S-1 becoming effective. Each debenture matures one year from date of issuance. The interest rate for each debenture is six percent (6%) per annum and the Debenture may be converted at the lesser of $0.30 per share or eighty percent (80%) of the lowest VWAP of the Company’s common stock for ten consecutive trading days immediately prior to the conversion date and carried an original discount of 3% of the debenture face value. The Company also issued a warrant to purchase 250,000 shares of the Company’s common stock for a period of two years, expiring on August 30, 2024, at an exercise price of $0.60 per share. As part of the agreement the Company filed an S-1 registration statement registering the underlying common shares for the debenture conversion and the warrants. The initial derivative was calculated using risk free interest of 3.47%, volatility of 137% and expected life of 1 year. During the year ended March 31, 2023, the Company issued 1,858,862 shares of common stock for the conversion of $200,000 of the convertible note. During the year ended March 31, 2024 the Company issued 871,323 shares of common stock with a value of $50,000 retiring the note. On December 1, 2023 the Company issued an amended convertible debenture to an unrelated third party under the agreement dated September 2, 2022 (noted in the paragraph above), totaling $250,000. The debenture had an original discount of 10% with no accrued interest and matures on May 30, 2024. The note is convertible into common stock of the Company at the rate of $0.10 per share. On December 6, 2023, the note holder converted $125,000 of the note into 1,250,000 shares of common stock of the Company. As of March 31, 2024, the outstanding balance of the note was $125,000. During the year ended March 31, 2024, the Company issued an aggregate of 10,787,180 shares of common stock with a value of $673,267 for the conversion of $470,000 of convertible note and $22,795 in interest. The conversion of the shares plus the principal payment noted above leaves a balance due of $125,000 in convertible notes plus accrued interest.

LICENSE AGREEMENT TERMINATION

LICENSE AGREEMENT TERMINATION	12 Months Ended
	Mar. 31, 2024
LICENSE AGREEMENT TERMINATION
LICENSE AGREEMENT TERMINATION	NOTE 11 – LICENSE AGREEMENT TERMINATION On March 31, 2021, the Company issued a license agreement for US $5,000,000 to BioRay Pharmaceutical Co, LTD, (Licensee) licensing Pritumumab internationally with the exclusion of North and Central America and the Caribbean Islands. Under the terms of the agreement the Company received $250,000 upon signing of the agreement plus $750,000 when the phase 1 clinical trial started in March 2021. In addition, the Company received $750,000 upon the initial patient enrolled at the dosage level of 8.0 mg/kg. Further payment of $2,500,000 were to be received when the FDA approves the phase 2 clinical trials and $750,000 when the phase 2 clinical trials was to begin. Upon commercialization by the Licensee, the Company would have received a 9% royalty on net sales for 20 years. As of March 31, 2023 the Company had received payments totaling $1,750,000 from the license agreement. On June 6, 2023 the Company signed a mutual agreement with BioRay Pharmaceutical Co to terminate the license agreement. The termination of the agreement rescinds all rights by BioRay and returns to the Company, the global rights, which had been granted BioRay under the agreement.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Mar. 31, 2024
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	NOTE 12 – COMMITMENTS AND CONTINGENCIES On June 30, 2016, the Company entered into a cell line sales agreement with the product manufacture. Under the terms of the agreement the company is obligated to make future payments based on the milestones of its achievements. These future payments may be as followed; 1. $100,000 upon the initiation (first dose/first patient) of the first Phase I clinical trial (or equivalent) of a product. 2. $225,000 upon the initiation (first dose/first patient) of the first Phase III clinical trial (or equivalent) of a product 3. $225,000 payable upon the first BLA approval (or equivalent) of a product. 4. Annual maintenance fee upon completion of phase I manufacturing or the transfer of the cell line from Catalent’s control of $50,000. 5. A contingent sales fee upon product sales of 1% of sales or $150,000 whichever is greater. As of March 31, 2024 the outstanding amount due the manufacture was zero On March 9, 2020, the Board of Directors of the Company adapted an expense bonus program. Under the program, if an acquisition, merger or change in control is affected, 10% of the value of the transaction will be allocated to pay the expenses of the transaction including but not limited to legal, accounting, transfer fees and other miscellaneous expense. The balance of the fund after expenses will be allocation 20% to directors and 80% to officers and employees of the Company as allocated by the Chief Executive Officer and approved by the Board of Directors. On September 1, 2020, the Company entered five-year compensation agreements with two of its officers and directors. Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers and directors are entitled to additional future shares so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Mar. 31, 2024
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	NOTE 13 – SUBSEQUENT EVENTS On March 29, 2024 the Company file an S-1 registering 20,000,000 share for offering at $0.15 per share. The S-1 became effective on April 8, 2024. On June 26, 2024, the Company issued 1,270,000 shares of common stock for the conversion of $63,500 of convertible debt. On June 27, 2024, the Company issued 338,000 shares of common stock with a value of $30,920 for service. The Company has evaluated subsequent events to determine events occurring after March 31, 2024 through the date this report was issued and determined there are no events that would have a material impact on the Company’s financial results or require disclosure and have determined none exist other than those noted above in this footnote.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Mar. 31, 2024
SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation	The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles. The Company has elected a fiscal year ending on March 31.
Principles of Consolidation	The accompanying consolidated financial statements include the accounts of Nascent Biotech, Inc. and its wholly-owned subsidiary Nascent Biologics, Inc, which has been inactive since March 2015. All intercompany accounts and transactions have been eliminated.
Cash and Cash Equivalents	The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company as of March 31, 2024 did not have any cash equivalents.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the periods. The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition, and results of operations is highly uncertain and subject to change. We considered the potential impact of the COVID-19 pandemic on our estimates and assumptions and there was not a material impact to our consolidated financial statements as of and for the year ended March 31, 2024. Actual results could differ from estimates making it reasonably possible that a change in the estimates could occur in the near term.
Revenue recognition	In April 2016, the FASB issued ASU 2016–10 Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. The amendments in this Update do not change the core principle of the guidance in Topic 606. Rather, the amendments in this Update clarify the following two aspects of Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. Topic 606 includes implementation guidance on (a) contracts with customers to transfer goods and services in exchange for consideration and (b) determining whether an entity’s promise to grant a license provides a customer with either a right to use the entity’s intellectual property (which is satisfied at a point in time) or a right to access the entity’s intellectual property (which is satisfied over time). The amendments are intended to render more detailed implementation guidance with the expectation to reduce the degree of judgement necessary to comply with Topic 606. ASC Topic 606 prescribes a new five-step model entities should follow in order to recognize revenue in accordance with the core principle. These five steps are: 1. Identify the contract(s) with a customer. 2. Identify the performance obligations in the contract. 3. Determine the transaction price. 4. Allocate the transaction price to the performance obligations in the contract. 5. Recognize revenue when (or as) the entity satisfied the performance obligations. The Company implemented the transition using the modified retrospective method of transition. The funds are not earned on milestones that have not been reached per the contract. Based on the cut off treatment of the recognition of revenue per the milestones specific to the license agreements, the Company has determined that there are no adjustments in the value of the revenue recognized from these contracts. The Company had one revenue stream, which was the milestone payments of the license agreement with BioRay Pharmaceutical which is not earned or billed until the milestone per the agreement is met. The license agreement for this revenue stream was terminated. The Company did not receive any revenue for the year ended March 31, 2024.
Stock-Based Compensation	The Company accounts for stock-based compensation in accordance with the fair value recognition provision of the Financial Accounting Standards Board(“FASB”) Accounting Standards Codification (“ASC”) No 718. The Company issues restricted stock to employees and consultants for their services. Cost of these transactions are measured at fair value of the equity instrument issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as the expense in the period granted. The Company recognized consulting expense and a corresponding increase to the additional paid in capital related to the stock issued for services. For agreements requiring future services the consulting expense is to be recognized ratably over the requisite service period.
Research and Development Expense	Research and development costs are expensed in the period they are incurred in accordance with ASC 730, Research and Development unless they meet specific criteria related to technical, market and financial feasibility, as determined by management, including but not limited to the establishment of a clearly defined future alternative use for the product, and the availability of adequate resources to complete the project. If all criteria are met, the costs are deferred and amortized over the expected useful life of the project or expensed as research and development as the material are consumed or written off if a product is abandoned. At March 31, 2024 and 2023, the Company had zero capitalization associated with materials held with a future alternative use. The cost of these materials was expensed as research and development as the materials are consumed or designated for usage. As the Company is preparing to begin clinical studies using a dose escalation method, it is not feasible to determine if the additional product will be needed for the brain cancer studies.
Income Taxes	Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company accounts for income taxes under the provisions of FASB ASC 740, Accounting for Income Taxes
Basic and Diluted Net Income (Loss) per Share	Basic net income (loss) per share calculations are calculated on the basis of the weighted average number of common shares outstanding during the year. During the year ended March 31, 2024 the Company had a net loss so the options and warrants outstanding were not part the loss per share calculation as they would be antidilutive. Diluted income (loss) per share calculations includes the dilutive effect of warrants and options on the weighted average of the per share calculation.
Fair Value of Financial Instruments	The Company’s financial instruments consist of cash and cash equivalents, accounts payable and accrued expenses and shareholder loans. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. As defined in (Financial Accounting Standards Board ASC 820), fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilized the market data of similar entities in its industry or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. FASB ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). The three levels of the fair value hierarchy are as follows: Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities, and listed equities. Level 2 - Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or indirectly observable as of the reported date and includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options, and collars. Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value As of March 31, 2024 the Company believes the amounts reported for cash, payables, accrued liabilities and amounts due to related parties approximate their fair values due to the nature or duration of these instruments. The following table represents the change in the fair value of the derivative liabilities during the year ended March 31, 2024: Level 1 Level 2 Level 3 Balance at March 31, 2022 $ - $ - $ - Change in fair value at initial issuance - - 178,739 Change in fair value at conversion (570,099 ) Change in fair value of the derivative - - 1,054,786 Balance at March 31, 2023 $ - $ - $ 663,426 Change in fair value at initial issuance - Change in fair value at conversion (191,258 ) Change in fair value of the derivative (472,168 ) Balance at March 31, 2024 $ - $ - $ -

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Mar. 31, 2024
SIGNIFICANT ACCOUNTING POLICIES
Schedule of Summarizes of change in the fair value of the derivative liabilities	Level 1 Level 2 Level 3 Balance at March 31, 2022 $ - $ - $ - Change in fair value at initial issuance - - 178,739 Change in fair value at conversion (570,099 ) Change in fair value of the derivative - - 1,054,786 Balance at March 31, 2023 $ - $ - $ 663,426 Change in fair value at initial issuance - Change in fair value at conversion (191,258 ) Change in fair value of the derivative (472,168 ) Balance at March 31, 2024 $ - $ - $ -

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	12 Months Ended
	Mar. 31, 2024
RELATED PARTY TRANSACTIONS
Schedule of shares earned by related party	Officer and Director Fiscal Year Annualized Compensation Base Being Paid Non-dilutive shares percentage President and CEO (2) $ 252,000 12 % Chief Financial Officer (1) $ 180,000 6 % Director (3) $ 20,000 - Total $ 452,000 18 % 24,000Officer and Director Initial Share Awards Under the Contracts Additional Shares Earned to Maintain Ownership Percentage Total Shares Earned President 1,028,910 14,712,669 15,741,579 Chief Financial Officer 617,346 7,588,673 8,206,019 Total 1,646,256 22,301,342 23,947,598

OPTIONS (Tables)

OPTIONS (Tables)	12 Months Ended
	Mar. 31, 2024
OPTIONS
Schedule of Summary of stock options outstanding	Options Weighted Average Exercise Price Weighted Average Remaining Contract Life Number of Options Exercisable Intrinsic Value Outstanding at March 31, 2022 930,000 $ 0.34 3.80 930,000 $ -- Granted 500,000 0.18 4.75 -- -- Exercised -- -- -- -- -- Forfeited -- -- -- -- -- Outstanding at March 31, 2023 1,430,000 $ 0.28 3.81 930,000 $ -- Granted -- -- -- -- -- Exercised (500,000 ) -- -- -- -- Forfeited -- -- -- -- Outstanding at March 31, 2024 930,000 $ 0.34 2.81 930,000 $ --

WARRANTS (Tables)

WARRANTS (Tables)	12 Months Ended
	Mar. 31, 2024
WARRANTS
Schedule of weighted average remaining life and intrinsic value of the warrants	Warrants Weighted Average Exercise Price Weighted Average Remaining Contract Life Intrinsic Value Outstanding at March 31, 2022 3,700,000 $ 0.04 1.35 $ - Granted 1,000,000 0.60 1.75 - Exercised (3,700,000 ) - -- - Expired -- - -- - Outstanding at March 31, 2023 1,000,000 $ 0.60 1.50 $ - Granted 250,000 0.60 2.75 Exercised -- - -- - Expired -- - -- - Outstanding at March 31, 2024 1,250,000 $ 0.16 .95 $ 134,500

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Mar. 31, 2024
INCOME TAXES
Schedule of Components of net deferred tax assets	March 31, 2024 March 31, 2023 Deferred tax assets: Net operating loss $ 1,238,858 $ 1,757,783 Less: Valuation allowance (1,238,858 ) (1,757,783 ) Net deferred tax assets $ - $ -

ORGANIZATION AND NATURE OF OP_2

ORGANIZATION AND NATURE OF OPERATIONS (Details Narrative) - USD ($)	Mar. 31, 2024	Mar. 31, 2023	Jul. 15, 2014
Common stock, outstanding shares	170,594,165	131,764,348
Jin-En [Member]
Common stock, issued shares			7,500,200
Common stock, shares cancelled			15,000,000
Common stock, outstanding shares			22,829,400
Net liablilities			$ 19,000

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Level 1 [Member]
Begnning Balance	$ 0	$ 0
Change in fair value at initial issuance	0	0
Change in fair value of the derivative	0	0
Ending Balance	0	0
Level 2 [Member]
Begnning Balance	0	0
Change in fair value at initial issuance	0	0
Ending Balance	0	0
Change in fair value at initial issuance and conversion		0
Change in fair value of the derivative	0	0
Level 3 [Member]
Begnning Balance	663,426	0
Change in fair value at initial issuance	0
Ending Balance	0	663,426
Change in fair value at initial issuance and conversion	(191,258)	178,739
Change in fair value at conversion		(570,099)
Change in fair value of the derivative	$ (472,168)	$ 1,054,786

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
GOING CONCERN
Working capital deficit	$ (256,674)
Accumulated Deficit	$ (24,260,457)	$ (21,622,775)

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details)	12 Months Ended
	Mar. 31, 2024 USD ($)
Fiscal Year Annualized Compensation Being Paid	$ 452,000
Non-dilutive shares, percentage	18%
President [Member]
Fiscal Year Annualized Compensation Being Paid	$ 252,000
Non-dilutive shares, percentage	12%
Chief Financial Officer [Member]
Fiscal Year Annualized Compensation Being Paid	$ 180,000
Non-dilutive shares, percentage	6%
Director [Member]
Fiscal Year Annualized Compensation Being Paid	$ 20,000
Non-dilutive shares, percentage	0%

RELATED PARTY TRANSACTIONS (D_2

RELATED PARTY TRANSACTIONS (Details 1)	12 Months Ended
	Mar. 31, 2024 shares
Initial Share Awards Under the Contracts	1,646,256
Additional Shares Earned to Maintain Ownership Percentage	22,301,342
Total Shares Earned	23,947,598
President [Member]
Initial Share Awards Under the Contracts	1,028,910
Additional Shares Earned to Maintain Ownership Percentage	14,712,669
Total Shares Earned	15,741,579
Chief Financial Officer [Member]
Initial Share Awards Under the Contracts	617,346
Additional Shares Earned to Maintain Ownership Percentage	7,588,673
Total Shares Earned	8,206,019

RELATED PARTY TRANSACTIONS (D_3

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Officers and directors employment agreement terms, description	Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers and directors are entitled to additional future shares so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company.
Common stock shares issued for services, shares	7,186,385	3,815,414
Common stock shares issued for services, amount	$ 773,241	$ 624,320
Chief Financial Officers [Member]
Cash	180,000
President And Chief Executive Officer [Member]
Cash	$ 252,000
Three Officers and Director [Member]
Accrued consulting fees		20,000
September 1, 2020 [Member]
Bonus amount		$ 170,000

LICENSE SETTLEMENT (Details Nar

LICENSE SETTLEMENT (Details Narrative) - Consulting Agreement [Member]	Oct. 12, 2017 USD ($) integer
Number of installments, consideration for license | integer	24
Monthly installment payment	$ 1,000
Consulting fees payable	$ 24,000

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Jul. 09, 2020	Jul. 10, 2019
Common stock shares issued during period for conversion of debt and accrued interest, shares	10,787,180	11,398,059
Common stock issued for service, shares	386,250
Common stock issued for service, amount	$ 35,850
Common stock shares issued during period for conversion of debt and accrued interest, amount	$ 684,054	$ 1,023,974
Common stock shares, issued	170,594,165	131,764,348
Conversion of convertible notes	$ 25,000
Conversion of convertible notes, shares	500,000
Common stock shares value for cash, amount	$ 1,561,000
Common stock shares value for cash, shares	19,970,000
Total no of authorized shares			550,000,000
Preferred stock shares authorized	50,000,000	50,000,000	50,000,000
Common stock shares authorized	500,000,000	500,000,000	500,000,000
Common stock shares par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock shares designated				1,500,000
Common stock shares issued during period	886,250
Common stock shares issued during period, value	$ 60,850
Three related parties [Member]
Common stock issued for service, shares	7,186,385	3,815,414
Common stock shares value for account payable, amount	$ 773,241	$ 624,320
clinical consulting [Member]
Common stock issued for service, shares		1,000,000
Common stock shares value for account payable, amount		$ 60,000
Accounts Payable [Member]
Common stock issued for service, shares		37,700
Common stock shares value for account payable, amount		$ 9,275
Warrant [Member]
Common stock shares, issued		4,200,000
Common stock issued for service, shares		4,200,000
Common stock shares value for account payable, amount		$ 208,000

OPTIONS (Details)

OPTIONS (Details) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Options
Number of option exercisable, Beginning	1,430,000	930,000
Outstanding option, Granted	0	500,000
Outstanding option, Exercised	(500,000)	0
Outstanding option, Forfeited	0	0
Number of option exercisable, Ending	930,000	930,000
Weighted average exercise price
Weighted average exercise price, Beginning	$ 0.28	$ 0.34
Weighted average exercise price granted	0	0.18
Weighted average exercise price, Ending	$ 0.34	$ 0.28
Weighted Average Remaining Contract Life
Weighted Average Remaining Contract life, Beginning	3 years 9 months 22 days	3 years 9 months 18 days
Weighted Average Remaining Contract life, granted		4 years 9 months
Weighted Average Remaining Contract life, Ending	2 years 9 months 21 days	3 years 9 months 21 days
Number of option exercisable
Outstanding option, Beginning	930,000	930,000
Outstanding option, Forfeited	0	0
Outstanding option, Ending	930,000	1,430,000
Intrinsic value
Intrinsic value, Beginning	$ 0	$ 0
Intrinsic value, Ending	$ 0	$ 0

OPTIONS (Details Narrative)

OPTIONS (Details Narrative)			1 Months Ended				12 Months Ended
	Sep. 02, 2022	Apr. 07, 2022	Jan. 30, 2024	Nov. 17, 2022 USD ($) $ / shares shares	Aug. 31, 2022	Jul. 20, 2016 USD ($) $ / shares shares	Mar. 31, 2024 USD ($) integer $ / shares shares	Mar. 31, 2023 USD ($)
Common stock exercisable term				5 years			10 years
Options vested description				The options have a 5 year life and vested 250,000 options at inception and 25,000 options per month thereafter until fully vested			The options vest in equal annual installments over a five year period with the first 20% vested when the options were granted
Exercise price of options | $ / shares				$ 0.10		$ 0.301
Option awards expences | $							$ 48,000	$ 72,000
Options granted						900,000
Issued options				500,000		300,000
Volatility rate	137%	132%	158%	250%	137%
Discount rate				4.35%
Fair value of option granted | $				$ 114,531		$ 484,205
Option accrued payables | $				$ 25,000
April 1, 2017 [Member] | Option 1 [Member]
Options granted							30,000
April 1, 2018 [Member]
Issued options							40,000
April 1, 2018 [Member] | Option 1 [Member]
Exercise price of options | $ / shares							$ 0.25
Options granted							40,000
Fair value of option granted | $							$ 9,991
April 1, 2016 [Member] | Option 1 [Member]
Common stock exercisable term							10 years
Exercise price of options | $ / shares							$ 0.30
Number of installments vest | integer							5
Issued options							40,000
April 1, 2016 [Member] | Option 2 [Member]
Common stock exercisable term							10 years
Exercise price of options | $ / shares							$ 0.30
Number of installments vest | integer							5
Options granted							30,000

WARRANTS (Details)

WARRANTS (Details) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Number of warrants
Outstanding warrants, Beginning	1,000,000	3,700,000
Outstanding warrants, granted	250,000	1,000,000
Outstanding warrants, Exercised		(3,700,000)
Outstanding warrants, Ending	1,250,000	1,000,000
Weighted average exercise price
Weighted average exercise price, Beginning	$ 0.60	$ 0.04
Weighted average exercise price, Granted	0.60	0.60
Weighted average exercise price, Exercised	0	0
Weighted average exercise price, Expired	0	0
Weighted average exercise price, Ending	$ 0.16	$ 0.60
Weighted Average Remaining Contract Life
Weighted Average Remaining Contract life, Beginning	1 year 5 months 30 days	1 year 4 months 6 days
Weighted Average Remaining Contract life, Granted	2 years 9 months	1 year 9 months
Weighted Average Remaining Contract life, Ending	11 months 12 days	1 year 6 months
Intrinsic value
Intrinsic value, Beginning	$ 0	$ 0
Intrinsic value, granted	0	0
Intrinsic value, Exercised	0	0
Intrinsic value, Expired	0	0
Intrinsic value, Ending	$ 134,500	$ 0

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - USD ($)			1 Months Ended			12 Months Ended
	Sep. 02, 2022	Apr. 07, 2022	Jan. 30, 2024	Nov. 17, 2022	Aug. 31, 2022	Mar. 31, 2024	Mar. 31, 2021	Mar. 31, 2023
Warrant Issued	250,000	500,000	250,000		750,000		3,700,000
Warrants issued as Series A convertible preferred shares							740,000
Warrant outstanding						1,250,000		1,000,000
Exercise price of warrants	$ 0.345	$ 0.08	$ 0.11		$ 0.41
Warrants conversion price	$ 0.60	$ 0.12	$ 0.60		$ 0.60		$ 0.15
Volatility rate	137%	132%	158%	250%	137%
Discount rate	3.47%	1.78%	5.20%		3.50%
Fair value of warrants	$ 50,273	$ 26,000	$ 18,280		$ 188,760
Adjustments to additional paid-in capital, warrant issued	$ 2,484	$ 21,336			$ 9,902
Warrant converted into common stock								500,000
Warrant converted into common stock, value								$ 60,000
Warrant converted								500,000
Deemed dividend						$ 550,000
Conversion price						$ 0.05
Coversion of Warrant to common stock			1,000,000
Warrant [Member]
Warrants conversion price							0.15
Change in warrants conversion price per share							$ 0.04
Fair value of warrants							$ 303,000
Deemed dividend from down round							555,000
Fair value of common stock							437,000
Proceeds from exercise of warrants							$ 349,605
Warrant [Member] | Minimum [Member]
Exercise price of warrants							$ 0.08
Volatility rate							312.50%
Discount rate							0.14%
Warrant [Member] | Maximum [Member]
Exercise price of warrants							$ 0.11
Volatility rate							314.49%
Discount rate							0.16%

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Deferred tax assets:
Net operating loss	$ 1,238,858	$ 1,757,783
Less: Valuation allowance	(1,238,858)	(1,757,783)
Net deferred tax assets	$ 0	$ 0

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
INCOME TAXES
Federal net operating loss carry forwards	$ 14,783,216	$ 13,544,358
Federal tax rate	21%	21%

CONVERTIBLE DEBT (Details Narra

CONVERTIBLE DEBT (Details Narrative) - USD ($)

1 Months Ended

12 Months Ended

Dec. 15, 2023

Dec. 06, 2023

Sep. 02, 2022

Apr. 07, 2022

Jan. 30, 2024

Oct. 30, 2023

Jun. 29, 2023

Nov. 17, 2022

Aug. 31, 2022

Mar. 31, 2024

Mar. 31, 2023

Sep. 27, 2022

Sep. 20, 2022

Convertible notes

$ 200,000

Volatility rate

137%

132%

158%

250%

137%

Common share issued

871,323

1,858,862

Common stock retiring note

$ 50,000

Issuance of aggregate shares of common stock, shares

170,594,165

131,764,348

Convertible common stock shares

1,000,000

Convertible common stock amount

$ 25,000

Convertible Debt [Member]

Conversion of convertible note

470,000

$ 800,000

Issuance of aggregate shares of common stock, value

$ 673,267

$ 823,975

Issuance of aggregate shares of common stock, shares

10,787,180

9,539,197

Conversion of convertible note interest

$ 22,795

$ 23,975

Convertible Notes Accrued Interest Debt [Member]

Accrued interest

$ 125,000

$ 700,000

Debtenture 1 [Member]

Risk free interest rate

3.50%

Volatility rate

137%

Expected life

1 year

Debtenture 2 [Member]

Risk free interest rate

4.03%

Volatility rate

140%

Expected life

1 year

Debtenture 3 [Member]

Risk free interest rate

3.98%

Volatility rate

141%

Expected life

1 year

August 31, 2022 [Member]

Conversion price, Description

Debenture may be converted at the lesser of $0.30 per share or eighty percent (80%) of the lowest VWAP of the Company’s common stock for ten consecutive trading days immediately prior to the conversion date and carried an original discount of 3% of the debenture face value

Warrant expiry date

Aug. 30, 2024

Exercise price of warrant

$ 0.60

Convertible debentures with unrelated party

$ 1,500,000

Debt paid, first installement

$ 500,000

Debt paid, second installement

$ 500,000

Interest rate on convertible debenture

6%

Common stock issued for warrant purchase

750,000

Debt paid, third installement

$ 500,000

September 02, 2022 [Member]

Conversion price, Description

Debenture may be converted at the lesser of $0.30 per share or eighty percent (80%) of the lowest VWAP of the Company’s common stock for ten consecutive trading days immediately prior to the conversion date and carried an original discount of 3% of the debenture face value

Risk free interest rate

3.47%

Volatility rate

137%

Expected life

1 year

Issuance of aggregate shares of common stock, shares

1,858,962

Warrant expiry date

Aug. 30, 2024

Exercise price of warrant

$ 0.60

Convertible debentures with unrelated party

$ 500,000

Debt paid, first installement

250,000

Debt paid, second installement

250,000

Interest rate on convertible debenture

6%

Common stock issued for warrant purchase

$ 250,000

December 1 2023 [Member]

Issuance amount of convertible debenture

$ 250,000

Discount rate

10%

Maturity date

May 30, 2024

Convertion price

$ 0.10

Convertible common stock shares

1,250,000

Convertible common stock amount

$ 125,000

Outstanding balance

$ 125,000

Debenture Redemption Agreement [Member]

Debenture redemption principal amount

$ 400,000

Debenture payment description

the Company paid the debenture owner $50,000 on August 24, 2023. The terms of the agreement requires principal payments of $50,000, which was made before September 30, 2023, $50,000 to be paid on or before October 31, 2023 and the balance of $250,000 on or before December 31, 2023

Description outstanding payment

On October 30, 2023 ,the Company paid $50,000 against the note outstanding per the settlement agreement leaving a balance due on December 31, 2023 of $250,000

Payment to related party debt

$ 250,000

LICENSE AGREEMENT TERMINATION (

LICENSE AGREEMENT TERMINATION (Details Narrative) - BioRay Pharmaceutical Co LTD [Member]	12 Months Ended
	Mar. 31, 2024 USD ($)
Agreement description	Under the terms of the agreement the Company received $250,000 upon signing of the agreement plus $750,000 when the phase 1 clinical trial started in March 2021. In addition, the Company received $750,000 upon the initial patient enrolled at the dosage level of 8.0 mg/kg. Further payment of $2,500,000 were to be received when the FDA approves the phase 2 clinical trials and $750,000 when the phase 2 clinical trials was to begin
License agreement, payments received	$ 1,750,000
Issuance of license agreement	$ 5,000,000
Royalty rate	9%
Royalty rate, net sales, term	20 years

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)		1 Months Ended		12 Months Ended
	Mar. 09, 2020	Sep. 30, 2020	Jun. 30, 2016	Mar. 31, 2024
Contingent sales fee description			A contingent sales fee upon product sales of 1% of sales or $150,000 whichever is greater
Merger, description	Under the program, if an acquisition, merger or change in control is affected, 10% of the value of the transaction will be allocated to pay the expenses of the transaction including but not limited to legal, accounting, transfer fees and other miscellaneous expense. The balance of the fund after expenses will be allocation 20% to directors and 80% to officers and employees of the Company as allocated by the Chief Executive Officer and approved by the Board of Directors	Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers and directors are entitled to additional future shares so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company
Annual Maintenance				$ 0
First Phase III clinical trial [Member]
Future payments			$ 225,000
First BLA [Member]
Future payments			225,000
First Phase I clinical trial [Member]
Future payments			100,000
Annual maintenance fee			$ 50,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Jun. 27, 2024	Jun. 26, 2024	Mar. 31, 2024	Mar. 31, 2023	Mar. 29, 2024
Offering price per share					$ 0.15
Initial pulic offering					20,000,000
Common stock issued for service, amount			$ 35,850	$ 60,000
Subsequent Event [Member]
Share issued for conversion		1,270,000
Share issued for conversion convertible debt		$ 63,500
Common stock issued for service, shares	338,000
Common stock issued for service, amount	$ 30,920